| scholarly article | Q13442814 |
| P2093 | author name string | Mahmut Uluganyan | |
| Ramazan Ozdemir | |||
| Nijad Bakhshaliyev | |||
| Asim Enhos | |||
| Erdem Karacop | |||
| P2860 | cites work | Azithromycin and the risk of cardiovascular death | Q24604355 |
| Comparing two types of macrolide antibiotics for the purpose of assessing population-based drug interactions | Q33163019 | ||
| Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia | Q33943151 | ||
| Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes | Q34633137 | ||
| Use of azithromycin and death from cardiovascular causes | Q34651195 | ||
| Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management | Q34992166 | ||
| Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery | Q35148912 | ||
| The pharmacokinetics of azithromycin and their clinical significance | Q36454251 | ||
| Antimicrobial-associated QT interval prolongation: pointes of interest | Q36655034 | ||
| A Novel Coronavirus from Patients with Pneumonia in China, 2019 | Q86729469 | ||
| Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial | Q87908797 | ||
| Discovering drugs to treat coronavirus disease 2019 (COVID-19) | Q87963364 | ||
| The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro | Q91598701 | ||
| Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment | Q91727332 | ||
| Hydroxychloroquine: from malaria to autoimmunity | Q37827403 | ||
| Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. | Q38283188 | ||
| Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine | Q41152773 | ||
| Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus | Q41916954 | ||
| Hypokalaemia related to acute chloroquine ingestion | Q41932450 | ||
| Insights from pharmacokinetic and pharmacodynamic studies of hydroxychloroquine. | Q41938698 | ||
| Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia | Q41945547 | ||
| Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes | Q44138918 | ||
| A case of QT-interval prolongation precipitated by azithromycin | Q44654507 | ||
| Azithromycin-induced torsade de pointes | Q46857435 | ||
| Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. | Q50988726 | ||
| [Clinical pharmacokinetics of azithromycin] | Q70830473 | ||
| Azithromycin-induced QT prolongation in elderly patient | Q79952556 | ||
| Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death | Q81239948 | ||
| P921 | main subject | azithromycin | Q165399 |
| COVID-19 | Q84263196 | ||
| P304 | page(s) | 59-64 | |
| P577 | publication date | 2020-08-11 | |
| P1433 | published in | Journal of Electrocardiology | Q2235085 |
| P1476 | title | The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients | |
| P478 | volume | 62 |
Search more.